Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

Slides:



Advertisements
Similar presentations
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation by Roberto.
Advertisements

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.
Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies.
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.
Gupta V, Tallman MS, Weisdorf DJ
A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation by Chunfu.
Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.
Long-term outcome after bone marrow transplantation for severe aplastic anemia by Lionel Ades, Jean-Yves Mary, Marie Robin, Christèle Ferry, Raphael Porcher,
Y. Hicheri, G. Cook, C. Cordonnier  Clinical Microbiology and Infection 
X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease by.
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Functional neutrophils from human ES cells
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.
Gut immune reconstitution in immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome after hematopoietic stem cell transplantation  Eleonora.
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation by Panagiotis D. Kottaridis, Donald W. Milligan,
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Y. Hicheri, G. Cook, C. Cordonnier  Clinical Microbiology and Infection 
Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation  Mats Remberger, Emma.
Sabina Kersting, Leo F. Verdonck 
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,
Allogeneic Haematopoietic Stem Cell Transplantation for Systemic Onset Juvenile Idiopathic Arthritis  Juliana Silva, MD, Julie Glanville, Fani Ladomenou,
Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program  Margaret L.
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience  Mary A.
The Saudi Experience in Fludarabine-Based Conditioning Regimens in Patients with Fanconi Anemia Undergoing Stem Cell Transplantation: Excellent Outcome.
Kasiani C. Myers, Stella M. Davies 
Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism  Mary.
Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.
Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.
Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation:
Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis by Juliana M. F. Silva, Fani Ladomenou, Ben Carpenter,
Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence  Keshav.
Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency  Amel Hassan,
What is quality in a transplant program?
Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.
HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category  Ann Woolfrey, Stephanie J.
T-cell receptor αβ+ and CD19+ cell–depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency  Ravi M.
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Volume 2(Supplement 1):46-49
by Michael R. DeBaun, and Ellen Wright Clayton
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation by Richard K. Burt, Ann.
Bridge to transplant following Bv+Bs regimen.
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.
Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better? 
Human Herpes Virus 6 Plasma DNA Positivity after Hematopoietic Stem Cell Transplantation in Children: an Important Risk Factor for Clinical Outcome  P.J.
William Berquist, MD  Gastrointestinal Endoscopy 
Outcome of hematopoietic stem cell transplantation for adenosine deaminase–deficient severe combined immunodeficiency by Amel Hassan, Claire Booth, Alex.
Effect of donor and recipient CMV serostatus on survival after HSCT in 2 large cohorts. Effect of donor and recipient CMV serostatus on survival after.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
by Lucy A. Godley, and Akiko Shimamura
by Jan J. Cornelissen, and Didier Blaise
Optimizing therapy for nodal marginal zone lymphoma
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Cold agglutinin disease
Presentation transcript:

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience by Mary A. Slatter, Kanchan Rao, Persis Amrolia, Terry Flood, Mario Abinun, Sophie Hambleton, Zohreh Nademi, Nick Goulden, Graham Davies, Waseem Qasim, Hubert B. Gaspar, Andrew Cant, Andrew R. Gennery, and Paul Veys Blood Volume 117(16): April 21, 2011 ©2011 by American Society of Hematology

Kaplan-Meier survival curve. Mary A. Slatter et al. Blood 2011;117: ©2011 by American Society of Hematology

Split cell chimerism in patients more than 1 year after HSCT. Of 42 patients, 24 (57%) had 100% donor chimerism in all cell lines: 15 of 26 (58%) in the fludarabine group and 9 of 16 (56%) in the cyclophosphamide group. Mary A. Slatter et al. Blood 2011;117: ©2011 by American Society of Hematology

Split cell chimerism in 42 patients more than 1 year after HSCT by disease. Mary A. Slatter et al. Blood 2011;117: ©2011 by American Society of Hematology

Split cell chimerism in MSD/MFD recipients more than 1 year after HSCT. Numbers are small (7 in fludarabine group and 5 in cyclophosphamide group), but there is a suggestion that chimerism is better after fludarabine in all cell lineages. Mary A. Slatter et al. Blood 2011;117: ©2011 by American Society of Hematology

Split cell chimerism in unrelated donor recipients more than 1 year after HSCT according to stem cell source. Mary A. Slatter et al. Blood 2011;117: ©2011 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.